CAMK2A and major depressive disorder: Taken together, our study provides additional evidence that extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model, which will contribute to the development of the next generation of more effective and safer antidepressants.